David A. Siegel Adaptimmune Therapeutics PLC Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Two Sigma Advisers, LP holds 11,948 shares of ADAP stock, worth $7,049. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,948

Previous 33,337 64.16%

Holding current value

$7,049

Previous $32,000 65.63%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.92 - $1.39 $19,677 - $29,730	-21,389 Reduced 64.16%	11,948 $11,000
Q2 2024 Aug 14, 2024	SELL	$0.83 - $1.47 $10,624 - $18,816	-12,800 Reduced 27.74%	33,337 $32,000
Q1 2024 May 15, 2024	SELL	$0.7 - $1.75 $9,590 - $23,975	-13,700 Reduced 22.9%	46,137 $72,000
Q4 2023 Feb 14, 2024	SELL	$0.43 - $0.79 $1,978 - $3,634	-4,600 Reduced 7.14%	59,837 $47,000
Q3 2023 Nov 14, 2023	SELL	$0.73 - $1.04 $23,725 - $33,800	-32,500 Reduced 33.53%	64,437 $50,000
Q2 2023 Aug 14, 2023	BUY	$0.9 - $1.51 $56,643 - $95,034	62,937 Added 185.11%	96,937 $89,000
Q1 2023 May 15, 2023	BUY	$1.06 - $2.16 $3,922 - $7,992	3,700 Added 12.21%	34,000 $37,000
Q4 2022 Feb 14, 2023	SELL	$1.05 - $2.53 $840 - $2,023	-800 Reduced 2.57%	30,300 $44,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $2.41 $4,452 - $10,122	-4,200 Reduced 11.9%	31,100 $33,000
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.28 $92,701 - $158,916	-69,700 Reduced 66.38%	35,300 $60,000
Q1 2022 May 16, 2022	BUY	$1.73 - $4.06 $181,650 - $426,299	105,000 New	105,000 $216,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

150M

Call Options Held

60.8K

Put Options Held

5.8K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $96.4M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account